Amphastar Pharmaceuticals (AMPH) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its earnings results on Monday, March 12th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03, Briefing.com reports. The company had revenue of $60.40 million during the quarter, compared to analysts’ expectations of $60.62 million. Amphastar Pharmaceuticals had a net margin of 1.88% and a return on equity of 4.56%. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.01 earnings per share.

AMPH stock traded up $0.12 on Thursday, hitting $19.14. 146,737 shares of the company were exchanged, compared to its average volume of 204,712. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.85 and a current ratio of 2.79. Amphastar Pharmaceuticals has a twelve month low of $13.15 and a twelve month high of $20.45. The firm has a market capitalization of $863.97, a price-to-earnings ratio of 50.37, a price-to-earnings-growth ratio of 1.33 and a beta of 1.42.

How to Become a New Pot Stock Millionaire

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 19,801 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $20.10, for a total transaction of $398,000.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jason B. Shandell sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $19.43, for a total transaction of $388,600.00. Following the sale, the insider now owns 251,372 shares of the company’s stock, valued at $4,884,157.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 84,387 shares of company stock valued at $1,659,763. 11.10% of the stock is owned by insiders.

AMPH has been the subject of a number of analyst reports. BidaskClub raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, January 19th. Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Wells Fargo reissued a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, March 21st. Piper Jaffray reissued a “buy” rating and issued a $26.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Tuesday, January 30th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $19.00 price target (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $21.33.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by BBNS and is owned by of BBNS. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://baseballnewssource.com/2018/04/05/amphastar-pharmaceuticals-amph-posts-earnings-results/2028935.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.